The Societal Burden of Sickle Cell Disease: A Life Course Perspective

Sickle cell disease (SCD) places a lifelong burden on patients and family members. Our objective was to review the available evidence to understand the impact of SCD across the life course, including childhood development, education, employment, quality of life, and life expectancy. This targeted literature review examined empirical studies from 2001 to 2026 that assessed the burden of SCD among patients and family caregivers across different life stages, including childhood, adolescence, adulthood, and older adulthood. Outcomes included early childhood development, education, labor market outcomes, life expectancy, and impact on family caregivers. Overall, 23 unique studies were included. Studies consistently demonstrated that SCD places a large burden on patients and family caregivers across all life stages, especially for those with recurrent vaso-occlusive crises. Many children with SCD experience significant developmental delays in cognition, while adolescents often experience greater school absenteeism, worse academic performance, and a higher likelihood of school dropout. Caregivers for children with SCD experience lost labor market opportunities and diminished mental health. Adults with SCD are less likely to work (unemployment), and when they do, they often have greater work absenteeism and presenteeism, worse job opportunities, and less income. Ultimately, people with SCD experience both lower overall life expectancy and lower quality of life. Patients with SCD experience a burden associated with the disease across the life course. These outcomes should inform future evaluations of treatment and supportive services for SCD, which have the potential to generate substantial societal value.

Authors

Institutions

Publication Details

Journal
Advances in Therapy
Published
2026-11-18
DOI
https://doi.org/10.1007/s12325-026-03862-3
Primary Topic
Hemoglobinopathies and Related Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Societal Burden of Sickle Cell Disease: A Life Course Perspective

David C. Grabowski, Arie Barlev, Darius Noshir Lakdawalla
Advances in Therapy
Hemoglobinopathies and Related Disorders
article

The Societal Burden of Sickle Cell Disease: A Life Course Perspective

David C. Grabowski, Arie Barlev, Darius Noshir Lakdawalla
article en

Abstract

Sickle cell disease (SCD) places a lifelong burden on patients and family members. Our objective was to review the available evidence to understand the impact of SCD across the life course, including childhood development, education, employment, quality of life, and life expectancy. This targeted literature review examined empirical studies from 2001 to 2026 that assessed the burden of SCD among patients and family caregivers across different life stages, including childhood, adolescence, adulthood, and older adulthood. Outcomes included early childhood development, education, labor market outcomes, life expectancy, and impact on family caregivers. Overall, 23 unique studies were included. Studies consistently demonstrated that SCD places a large burden on patients and family caregivers across all life stages, especially for those with recurrent vaso-occlusive crises. Many children with SCD experience significant developmental delays in cognition, while adolescents often experience greater school absenteeism, worse academic performance, and a higher likelihood of school dropout. Caregivers for children with SCD experience lost labor market opportunities and diminished mental health. Adults with SCD are less likely to work (unemployment), and when they do, they often have greater work absenteeism and presenteeism, worse job opportunities, and less income. Ultimately, people with SCD experience both lower overall life expectancy and lower quality of life. Patients with SCD experience a burden associated with the disease across the life course. These outcomes should inform future evaluations of treatment and supportive services for SCD, which have the potential to generate substantial societal value.

Advances in Therapy
Harvard University (US), Entegris (United States) (US), Vertex Pharmaceuticals (United States) (US)
Hemoglobinopathies and Related Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon